jrnls.org logo
Submit

BROWSE ALL JOURNALS

SEE ALL 19 JOURNALS
Journal of Pharmacology and PharmacotherapeuticsNOW IN
Article

Intrahepatic cholestasis in Bruton’s agammaglobulinemia receiving mesalamine for co-morbid Crohn’s disease

Giovanni Clemente Actis1★, Rinaldo Pellicano2, Floriano Rosina2★ Corresponding author

  1. 1Department of Gastro-Hepatology, Ospedale Gradenigo, Corso Regina Margherita 8, 10153 Torino, Italy.
  2. 2Department of Gastroenterology, Ospedale San Giovanni Battista (Molinette), C. Bramante 88, 10126 Torino, Italy.

CORRESPONDENCE

Giovanni Clemente Actis

Department of Gastro-Hepatology, Ospedale Gradenigo, Corso Regina Margherita 8, 10153 Torino, Italy.

actis_g@libero.it

Received: 03-08-2013; Revised: 15-11-2013; Accepted: 17-01-2014.

Volume 5, Issue 2 · pp. 151–152 · PUBLISHED 2014 · DOI: 10.4103/0976-500X.130071

View on JPP original site ↗

ABSTRACT

The salicylate derivatives mesalamines are used to treat both ulcerative colitis and Crohn’s disease. Mesalamines are almost devoid of toxicity, apart from very low figures of nephrotoxicity as derived from large population surveys. Indeed, meticulous analysis of the literature reveals some almost anecdotal cases of cholestatic hepatitis in inflammatory bowel disease (IBD) patients receiving these drugs. We recently encountered one of such patients and we thought it worth describing him, owing to the presence of a peculiar co-morbidity.

KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Actis, G. C., Pellicano, R., & Rosina, F. (2014). Intrahepatic cholestasis in Bruton’s agammaglobulinemia receiving mesalamine for co-morbid Crohn’s disease. Journal of Pharmacology and Pharmacotherapeutics, 5(2), 151–152. https://doi.org/10.4103/0976-500X.130071